Drug pipeline: Q312

The long-awaited thumbs-up for a gene therapy finally came through, with the November approval by the EMA of Glybera (alipogene tiparvovec) for patients lacking lipoprotein lipase. Other notable approvals are Aubagio (teraflunomide), the second small-molecule drug for multiple sclerosis, and Kyprolis (carfilzomib), an irreversible proteasome inhibitor for multiple myeloma. Some drugs addressing unmet oncology needs (pancreatic and mesothelioma) are showing positive signs in trials, and the first systemic antisense drug, Kynamro (mipomersen sodium), will be going before the FDA shortly.

FDA approvals by drug molecule type

Notable setbacks (Q3 2012)

Notable clinical trial results (Q3 2012)

Notable regulatory approvals (Q3 2012)

Notable upcoming regulatory decisions (Q1 2013)

Author information



Rights and permissions

Reprints and Permissions

About this article

Cite this article

DeFrancesco, L. Drug pipeline: Q312. Nat Biotechnol 30, 1164 (2012). https://doi.org/10.1038/nbt.2446

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing